nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—KIT—thymus cancer	0.604	1	CbGaD
Dasatinib—Oligomenorrhoea—Octreotide—thymus cancer	0.0114	0.108	CcSEcCtD
Dasatinib—VIIth nerve paralysis—Octreotide—thymus cancer	0.00431	0.0406	CcSEcCtD
Dasatinib—Cholecystitis—Octreotide—thymus cancer	0.00308	0.029	CcSEcCtD
Dasatinib—Haematoma—Octreotide—thymus cancer	0.00281	0.0265	CcSEcCtD
Dasatinib—Nail disorder—Octreotide—thymus cancer	0.00272	0.0257	CcSEcCtD
Dasatinib—Blood creatine phosphokinase increased—Octreotide—thymus cancer	0.00257	0.0242	CcSEcCtD
Dasatinib—Cholestasis—Octreotide—thymus cancer	0.00233	0.0219	CcSEcCtD
Dasatinib—Coagulopathy—Octreotide—thymus cancer	0.00227	0.0214	CcSEcCtD
Dasatinib—Petechiae—Octreotide—thymus cancer	0.00215	0.0202	CcSEcCtD
Dasatinib—Neoplasm malignant—Octreotide—thymus cancer	0.00207	0.0195	CcSEcCtD
Dasatinib—Contusion—Octreotide—thymus cancer	0.00203	0.0191	CcSEcCtD
Dasatinib—Neuropathy—Octreotide—thymus cancer	0.00166	0.0156	CcSEcCtD
Dasatinib—Gynaecomastia—Octreotide—thymus cancer	0.00158	0.0149	CcSEcCtD
Dasatinib—Thrombophlebitis—Octreotide—thymus cancer	0.00148	0.014	CcSEcCtD
Dasatinib—Cardiac failure congestive—Octreotide—thymus cancer	0.00141	0.0133	CcSEcCtD
Dasatinib—Amnesia—Octreotide—thymus cancer	0.00137	0.0129	CcSEcCtD
Dasatinib—Visual disturbance—Octreotide—thymus cancer	0.00135	0.0128	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00128	0.0121	CcSEcCtD
Dasatinib—Dry skin—Octreotide—thymus cancer	0.00118	0.0111	CcSEcCtD
Dasatinib—Gastritis—Octreotide—thymus cancer	0.00114	0.0107	CcSEcCtD
Dasatinib—Muscular weakness—Octreotide—thymus cancer	0.00113	0.0107	CcSEcCtD
Dasatinib—Abdominal distension—Octreotide—thymus cancer	0.00112	0.0105	CcSEcCtD
Dasatinib—Asthma—Octreotide—thymus cancer	0.00111	0.0104	CcSEcCtD
Dasatinib—Bronchospasm—Octreotide—thymus cancer	0.00109	0.0103	CcSEcCtD
Dasatinib—Pancreatitis—Octreotide—thymus cancer	0.00109	0.0102	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Octreotide—thymus cancer	0.00103	0.00971	CcSEcCtD
Dasatinib—Pollakiuria—Octreotide—thymus cancer	0.00102	0.00965	CcSEcCtD
Dasatinib—Weight increased—Octreotide—thymus cancer	0.00101	0.00951	CcSEcCtD
Dasatinib—Weight decreased—Octreotide—thymus cancer	0.001	0.00945	CcSEcCtD
Dasatinib—Pneumonia—Octreotide—thymus cancer	0.000994	0.00937	CcSEcCtD
Dasatinib—Neuropathy peripheral—Octreotide—thymus cancer	0.000969	0.00913	CcSEcCtD
Dasatinib—Conjunctivitis—Octreotide—thymus cancer	0.000961	0.00905	CcSEcCtD
Dasatinib—Haematuria—Octreotide—thymus cancer	0.000942	0.00888	CcSEcCtD
Dasatinib—Hepatobiliary disease—Octreotide—thymus cancer	0.000935	0.00881	CcSEcCtD
Dasatinib—Epistaxis—Octreotide—thymus cancer	0.000932	0.00879	CcSEcCtD
Dasatinib—Hepatitis—Octreotide—thymus cancer	0.000887	0.00836	CcSEcCtD
Dasatinib—Oedema peripheral—Octreotide—thymus cancer	0.000874	0.00824	CcSEcCtD
Dasatinib—Visual impairment—Octreotide—thymus cancer	0.000855	0.00806	CcSEcCtD
Dasatinib—Tinnitus—Octreotide—thymus cancer	0.000827	0.0078	CcSEcCtD
Dasatinib—Cardiac disorder—Octreotide—thymus cancer	0.000824	0.00776	CcSEcCtD
Dasatinib—Flushing—Octreotide—thymus cancer	0.000824	0.00776	CcSEcCtD
Dasatinib—Immune system disorder—Octreotide—thymus cancer	0.000802	0.00755	CcSEcCtD
Dasatinib—Arrhythmia—Octreotide—thymus cancer	0.000793	0.00747	CcSEcCtD
Dasatinib—Alopecia—Octreotide—thymus cancer	0.000784	0.00739	CcSEcCtD
Dasatinib—Mental disorder—Octreotide—thymus cancer	0.000777	0.00733	CcSEcCtD
Dasatinib—Malnutrition—Octreotide—thymus cancer	0.000772	0.00728	CcSEcCtD
Dasatinib—Erythema—Octreotide—thymus cancer	0.000772	0.00728	CcSEcCtD
Dasatinib—Muscle spasms—Octreotide—thymus cancer	0.000743	0.007	CcSEcCtD
Dasatinib—Vision blurred—Octreotide—thymus cancer	0.000728	0.00686	CcSEcCtD
Dasatinib—Tremor—Octreotide—thymus cancer	0.000724	0.00682	CcSEcCtD
Dasatinib—Ill-defined disorder—Octreotide—thymus cancer	0.000717	0.00675	CcSEcCtD
Dasatinib—Anaemia—Octreotide—thymus cancer	0.000714	0.00673	CcSEcCtD
Dasatinib—Malaise—Octreotide—thymus cancer	0.000697	0.00656	CcSEcCtD
Dasatinib—Vertigo—Octreotide—thymus cancer	0.000694	0.00654	CcSEcCtD
Dasatinib—Syncope—Octreotide—thymus cancer	0.000693	0.00653	CcSEcCtD
Dasatinib—Palpitations—Octreotide—thymus cancer	0.000683	0.00643	CcSEcCtD
Dasatinib—Loss of consciousness—Octreotide—thymus cancer	0.000679	0.0064	CcSEcCtD
Dasatinib—Cough—Octreotide—thymus cancer	0.000674	0.00635	CcSEcCtD
Dasatinib—Convulsion—Octreotide—thymus cancer	0.000669	0.00631	CcSEcCtD
Dasatinib—Hypertension—Octreotide—thymus cancer	0.000667	0.00628	CcSEcCtD
Dasatinib—Chest pain—Octreotide—thymus cancer	0.000658	0.0062	CcSEcCtD
Dasatinib—Myalgia—Octreotide—thymus cancer	0.000658	0.0062	CcSEcCtD
Dasatinib—Arthralgia—Octreotide—thymus cancer	0.000658	0.0062	CcSEcCtD
Dasatinib—Anxiety—Octreotide—thymus cancer	0.000655	0.00618	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000653	0.00615	CcSEcCtD
Dasatinib—Discomfort—Octreotide—thymus cancer	0.00065	0.00612	CcSEcCtD
Dasatinib—Oedema—Octreotide—thymus cancer	0.00063	0.00594	CcSEcCtD
Dasatinib—Infection—Octreotide—thymus cancer	0.000626	0.0059	CcSEcCtD
Dasatinib—Shock—Octreotide—thymus cancer	0.00062	0.00584	CcSEcCtD
Dasatinib—Nervous system disorder—Octreotide—thymus cancer	0.000618	0.00583	CcSEcCtD
Dasatinib—Thrombocytopenia—Octreotide—thymus cancer	0.000617	0.00582	CcSEcCtD
Dasatinib—Tachycardia—Octreotide—thymus cancer	0.000615	0.0058	CcSEcCtD
Dasatinib—Skin disorder—Octreotide—thymus cancer	0.000612	0.00577	CcSEcCtD
Dasatinib—Hyperhidrosis—Octreotide—thymus cancer	0.000609	0.00574	CcSEcCtD
Dasatinib—STK36—pituitary gland—thymus cancer	0.000601	0.00391	CbGeAlD
Dasatinib—Anorexia—Octreotide—thymus cancer	0.000601	0.00566	CcSEcCtD
Dasatinib—EPHA3—lung—thymus cancer	0.000598	0.00389	CbGeAlD
Dasatinib—ZAK—thyroid gland—thymus cancer	0.000596	0.00387	CbGeAlD
Dasatinib—EPHB1—lymph node—thymus cancer	0.000595	0.00386	CbGeAlD
Dasatinib—EPHB4—hematopoietic system—thymus cancer	0.000592	0.00384	CbGeAlD
Dasatinib—JAK2—hematopoietic system—thymus cancer	0.000587	0.00382	CbGeAlD
Dasatinib—SIK3—lung—thymus cancer	0.000582	0.00378	CbGeAlD
Dasatinib—LIMK2—pituitary gland—thymus cancer	0.000581	0.00378	CbGeAlD
Dasatinib—EPHA2—hematopoietic system—thymus cancer	0.00058	0.00377	CbGeAlD
Dasatinib—FYN—hematopoietic system—thymus cancer	0.000579	0.00376	CbGeAlD
Dasatinib—STK35—cardiac atrium—thymus cancer	0.000577	0.00375	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.000574	0.00541	CcSEcCtD
Dasatinib—CSK—cardiac atrium—thymus cancer	0.000573	0.00372	CbGeAlD
Dasatinib—BMPR1B—thyroid gland—thymus cancer	0.000571	0.00371	CbGeAlD
Dasatinib—MAPK14—epithelium—thymus cancer	0.00057	0.00371	CbGeAlD
Dasatinib—Insomnia—Octreotide—thymus cancer	0.00057	0.00537	CcSEcCtD
Dasatinib—BTK—bone marrow—thymus cancer	0.00057	0.0037	CbGeAlD
Dasatinib—BTK—thyroid gland—thymus cancer	0.000568	0.00369	CbGeAlD
Dasatinib—MAP4K5—hematopoietic system—thymus cancer	0.000566	0.00368	CbGeAlD
Dasatinib—MAP3K3—hematopoietic system—thymus cancer	0.000566	0.00368	CbGeAlD
Dasatinib—Dyspnoea—Octreotide—thymus cancer	0.000562	0.0053	CcSEcCtD
Dasatinib—Somnolence—Octreotide—thymus cancer	0.00056	0.00528	CcSEcCtD
Dasatinib—TNK2—thyroid gland—thymus cancer	0.00056	0.00364	CbGeAlD
Dasatinib—CSK—pituitary gland—thymus cancer	0.00056	0.00364	CbGeAlD
Dasatinib—Dyspepsia—Octreotide—thymus cancer	0.000555	0.00523	CcSEcCtD
Dasatinib—HCK—pituitary gland—thymus cancer	0.000552	0.00359	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—thymus cancer	0.000552	0.00358	CbGeAlD
Dasatinib—KIT—neck—thymus cancer	0.000551	0.00358	CbGeAlD
Dasatinib—ABL2—pituitary gland—thymus cancer	0.000549	0.00357	CbGeAlD
Dasatinib—Decreased appetite—Octreotide—thymus cancer	0.000548	0.00516	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000544	0.00513	CcSEcCtD
Dasatinib—Fatigue—Octreotide—thymus cancer	0.000544	0.00512	CcSEcCtD
Dasatinib—ZAK—lung—thymus cancer	0.000541	0.00352	CbGeAlD
Dasatinib—EPHB4—epithelium—thymus cancer	0.000541	0.00351	CbGeAlD
Dasatinib—Constipation—Octreotide—thymus cancer	0.000539	0.00508	CcSEcCtD
Dasatinib—Pain—Octreotide—thymus cancer	0.000539	0.00508	CcSEcCtD
Dasatinib—PDGFRB—neck—thymus cancer	0.000538	0.0035	CbGeAlD
Dasatinib—JAK2—epithelium—thymus cancer	0.000537	0.00349	CbGeAlD
Dasatinib—RIPK2—cardiac atrium—thymus cancer	0.000532	0.00345	CbGeAlD
Dasatinib—CSK—lymphoid tissue—thymus cancer	0.000531	0.00345	CbGeAlD
Dasatinib—EPHA2—epithelium—thymus cancer	0.000531	0.00345	CbGeAlD
Dasatinib—TESK1—thyroid gland—thymus cancer	0.000527	0.00342	CbGeAlD
Dasatinib—HCK—lymphoid tissue—thymus cancer	0.000524	0.00341	CbGeAlD
Dasatinib—YES1—hematopoietic system—thymus cancer	0.000523	0.0034	CbGeAlD
Dasatinib—Feeling abnormal—Octreotide—thymus cancer	0.00052	0.0049	CcSEcCtD
Dasatinib—RIPK2—pituitary gland—thymus cancer	0.000519	0.00337	CbGeAlD
Dasatinib—SIK1—cardiac atrium—thymus cancer	0.000519	0.00337	CbGeAlD
Dasatinib—MAP3K19—lung—thymus cancer	0.000519	0.00337	CbGeAlD
Dasatinib—BMPR1B—lung—thymus cancer	0.000519	0.00337	CbGeAlD
Dasatinib—STK36—thyroid gland—thymus cancer	0.000518	0.00337	CbGeAlD
Dasatinib—BTK—lung—thymus cancer	0.000516	0.00335	CbGeAlD
Dasatinib—Gastrointestinal pain—Octreotide—thymus cancer	0.000516	0.00486	CcSEcCtD
Dasatinib—EPHA4—cardiac atrium—thymus cancer	0.000514	0.00334	CbGeAlD
Dasatinib—PDGFRA—hematopoietic system—thymus cancer	0.000513	0.00333	CbGeAlD
Dasatinib—TNK2—lung—thymus cancer	0.000509	0.0033	CbGeAlD
Dasatinib—SIK1—pituitary gland—thymus cancer	0.000507	0.0033	CbGeAlD
Dasatinib—SRC—hematopoietic system—thymus cancer	0.000503	0.00327	CbGeAlD
Dasatinib—EPHA4—pituitary gland—thymus cancer	0.000502	0.00326	CbGeAlD
Dasatinib—LIMK2—thyroid gland—thymus cancer	0.000501	0.00325	CbGeAlD
Dasatinib—Urticaria—Octreotide—thymus cancer	0.000501	0.00472	CcSEcCtD
Dasatinib—BMX—lymph node—thymus cancer	0.0005	0.00325	CbGeAlD
Dasatinib—Abdominal pain—Octreotide—thymus cancer	0.000498	0.0047	CcSEcCtD
Dasatinib—Body temperature increased—Octreotide—thymus cancer	0.000498	0.0047	CcSEcCtD
Dasatinib—BLK—lymph node—thymus cancer	0.000494	0.00321	CbGeAlD
Dasatinib—STK35—thyroid gland—thymus cancer	0.000486	0.00315	CbGeAlD
Dasatinib—CSK—bone marrow—thymus cancer	0.000484	0.00314	CbGeAlD
Dasatinib—CSK—thyroid gland—thymus cancer	0.000482	0.00313	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—thymus cancer	0.000481	0.00313	CbGeAlD
Dasatinib—TESK1—lung—thymus cancer	0.000478	0.00311	CbGeAlD
Dasatinib—HCK—bone marrow—thymus cancer	0.000477	0.0031	CbGeAlD
Dasatinib—HCK—thyroid gland—thymus cancer	0.000476	0.00309	CbGeAlD
Dasatinib—ABL2—thyroid gland—thymus cancer	0.000473	0.00307	CbGeAlD
Dasatinib—TXK—lymph node—thymus cancer	0.000473	0.00307	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—thymus cancer	0.000472	0.00307	CbGeAlD
Dasatinib—STK36—lung—thymus cancer	0.000471	0.00306	CbGeAlD
Dasatinib—EPHB3—lung—thymus cancer	0.000471	0.00306	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—thymus cancer	0.000467	0.00304	CbGeAlD
Dasatinib—Hypersensitivity—Octreotide—thymus cancer	0.000464	0.00438	CcSEcCtD
Dasatinib—MAPK14—pituitary gland—thymus cancer	0.000463	0.00301	CbGeAlD
Dasatinib—FGR—pituitary gland—thymus cancer	0.000461	0.003	CbGeAlD
Dasatinib—SRC—epithelium—thymus cancer	0.00046	0.00299	CbGeAlD
Dasatinib—LIMK2—lung—thymus cancer	0.000455	0.00296	CbGeAlD
Dasatinib—Asthenia—Octreotide—thymus cancer	0.000452	0.00426	CcSEcCtD
Dasatinib—CSF1R—hematopoietic system—thymus cancer	0.000452	0.00293	CbGeAlD
Dasatinib—EPHB4—cardiac atrium—thymus cancer	0.000449	0.00292	CbGeAlD
Dasatinib—RIPK2—bone marrow—thymus cancer	0.000449	0.00292	CbGeAlD
Dasatinib—RIPK2—thyroid gland—thymus cancer	0.000448	0.00291	CbGeAlD
Dasatinib—JAK2—cardiac atrium—thymus cancer	0.000446	0.0029	CbGeAlD
Dasatinib—Pruritus—Octreotide—thymus cancer	0.000446	0.0042	CcSEcCtD
Dasatinib—FMO3—pituitary gland—thymus cancer	0.000445	0.00289	CbGeAlD
Dasatinib—STAT5B—lymph node—thymus cancer	0.000443	0.00288	CbGeAlD
Dasatinib—STK35—lung—thymus cancer	0.000441	0.00287	CbGeAlD
Dasatinib—EPHA2—cardiac atrium—thymus cancer	0.000441	0.00286	CbGeAlD
Dasatinib—FYN—cardiac atrium—thymus cancer	0.00044	0.00286	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—thymus cancer	0.000439	0.00285	CbGeAlD
Dasatinib—EPHB4—pituitary gland—thymus cancer	0.000439	0.00285	CbGeAlD
Dasatinib—SIK1—bone marrow—thymus cancer	0.000438	0.00285	CbGeAlD
Dasatinib—CSK—lung—thymus cancer	0.000438	0.00285	CbGeAlD
Dasatinib—FGR—lymphoid tissue—thymus cancer	0.000438	0.00284	CbGeAlD
Dasatinib—SIK1—thyroid gland—thymus cancer	0.000437	0.00284	CbGeAlD
Dasatinib—JAK2—pituitary gland—thymus cancer	0.000436	0.00283	CbGeAlD
Dasatinib—EPHA4—thyroid gland—thymus cancer	0.000433	0.00281	CbGeAlD
Dasatinib—HCK—lung—thymus cancer	0.000433	0.00281	CbGeAlD
Dasatinib—Diarrhoea—Octreotide—thymus cancer	0.000431	0.00406	CcSEcCtD
Dasatinib—EPHA2—pituitary gland—thymus cancer	0.000431	0.0028	CbGeAlD
Dasatinib—MAP3K3—cardiac atrium—thymus cancer	0.00043	0.00279	CbGeAlD
Dasatinib—MAP4K5—cardiac atrium—thymus cancer	0.00043	0.00279	CbGeAlD
Dasatinib—ABL2—lung—thymus cancer	0.00043	0.00279	CbGeAlD
Dasatinib—FYN—pituitary gland—thymus cancer	0.00043	0.00279	CbGeAlD
Dasatinib—ERBB3—thyroid gland—thymus cancer	0.000429	0.00278	CbGeAlD
Dasatinib—MAP3K2—bone marrow—thymus cancer	0.000426	0.00276	CbGeAlD
Dasatinib—MAP3K2—thyroid gland—thymus cancer	0.000424	0.00276	CbGeAlD
Dasatinib—MAP4K5—pituitary gland—thymus cancer	0.00042	0.00273	CbGeAlD
Dasatinib—MAP3K3—pituitary gland—thymus cancer	0.00042	0.00273	CbGeAlD
Dasatinib—Dizziness—Octreotide—thymus cancer	0.000417	0.00393	CcSEcCtD
Dasatinib—JAK2—lymphoid tissue—thymus cancer	0.000414	0.00269	CbGeAlD
Dasatinib—EPHB6—cardiac atrium—thymus cancer	0.000411	0.00267	CbGeAlD
Dasatinib—KIT—hematopoietic system—thymus cancer	0.00041	0.00266	CbGeAlD
Dasatinib—EPHA3—lymph node—thymus cancer	0.000409	0.00266	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—thymus cancer	0.000409	0.00265	CbGeAlD
Dasatinib—FYN—lymphoid tissue—thymus cancer	0.000408	0.00265	CbGeAlD
Dasatinib—RIPK2—lung—thymus cancer	0.000407	0.00264	CbGeAlD
Dasatinib—EPHB6—pituitary gland—thymus cancer	0.000401	0.00261	CbGeAlD
Dasatinib—Vomiting—Octreotide—thymus cancer	0.000401	0.00378	CcSEcCtD
Dasatinib—PDGFRB—hematopoietic system—thymus cancer	0.000401	0.0026	CbGeAlD
Dasatinib—MAPK14—bone marrow—thymus cancer	0.0004	0.0026	CbGeAlD
Dasatinib—MAPK14—thyroid gland—thymus cancer	0.000399	0.00259	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—thymus cancer	0.000399	0.00259	CbGeAlD
Dasatinib—FGR—bone marrow—thymus cancer	0.000398	0.00259	CbGeAlD
Dasatinib—LCK—bone marrow—thymus cancer	0.000398	0.00259	CbGeAlD
Dasatinib—SIK3—lymph node—thymus cancer	0.000398	0.00259	CbGeAlD
Dasatinib—Rash—Octreotide—thymus cancer	0.000397	0.00375	CcSEcCtD
Dasatinib—FGR—thyroid gland—thymus cancer	0.000397	0.00258	CbGeAlD
Dasatinib—LCK—thyroid gland—thymus cancer	0.000397	0.00258	CbGeAlD
Dasatinib—Dermatitis—Octreotide—thymus cancer	0.000397	0.00374	CcSEcCtD
Dasatinib—SIK1—lung—thymus cancer	0.000397	0.00258	CbGeAlD
Dasatinib—YES1—cardiac atrium—thymus cancer	0.000397	0.00258	CbGeAlD
Dasatinib—Headache—Octreotide—thymus cancer	0.000395	0.00372	CcSEcCtD
Dasatinib—EPHA4—lung—thymus cancer	0.000393	0.00255	CbGeAlD
Dasatinib—ERBB3—lung—thymus cancer	0.000389	0.00253	CbGeAlD
Dasatinib—YES1—pituitary gland—thymus cancer	0.000388	0.00252	CbGeAlD
Dasatinib—MAP3K2—lung—thymus cancer	0.000386	0.0025	CbGeAlD
Dasatinib—FMO3—thyroid gland—thymus cancer	0.000384	0.00249	CbGeAlD
Dasatinib—SRC—cardiac atrium—thymus cancer	0.000382	0.00248	CbGeAlD
Dasatinib—EPHB4—bone marrow—thymus cancer	0.000379	0.00246	CbGeAlD
Dasatinib—EPHB4—thyroid gland—thymus cancer	0.000378	0.00246	CbGeAlD
Dasatinib—JAK2—bone marrow—thymus cancer	0.000377	0.00245	CbGeAlD
Dasatinib—JAK2—thyroid gland—thymus cancer	0.000376	0.00244	CbGeAlD
Dasatinib—KIT—epithelium—thymus cancer	0.000375	0.00244	CbGeAlD
Dasatinib—Nausea—Octreotide—thymus cancer	0.000374	0.00353	CcSEcCtD
Dasatinib—FYN—bone marrow—thymus cancer	0.000371	0.00241	CbGeAlD
Dasatinib—EPHA2—thyroid gland—thymus cancer	0.000371	0.00241	CbGeAlD
Dasatinib—FYN—thyroid gland—thymus cancer	0.00037	0.00241	CbGeAlD
Dasatinib—ZAK—lymph node—thymus cancer	0.00037	0.0024	CbGeAlD
Dasatinib—YES1—lymphoid tissue—thymus cancer	0.000368	0.00239	CbGeAlD
Dasatinib—PDGFRB—epithelium—thymus cancer	0.000366	0.00238	CbGeAlD
Dasatinib—MAP4K5—bone marrow—thymus cancer	0.000363	0.00236	CbGeAlD
Dasatinib—MAP3K3—bone marrow—thymus cancer	0.000363	0.00236	CbGeAlD
Dasatinib—MAPK14—lung—thymus cancer	0.000362	0.00235	CbGeAlD
Dasatinib—MAP4K5—thyroid gland—thymus cancer	0.000362	0.00235	CbGeAlD
Dasatinib—MAP3K3—thyroid gland—thymus cancer	0.000362	0.00235	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—thymus cancer	0.000361	0.00235	CbGeAlD
Dasatinib—FGR—lung—thymus cancer	0.000361	0.00235	CbGeAlD
Dasatinib—LCK—lung—thymus cancer	0.000361	0.00235	CbGeAlD
Dasatinib—ABL1—hematopoietic system—thymus cancer	0.000357	0.00232	CbGeAlD
Dasatinib—BMPR1B—lymph node—thymus cancer	0.000355	0.0023	CbGeAlD
Dasatinib—SRC—lymphoid tissue—thymus cancer	0.000354	0.0023	CbGeAlD
Dasatinib—BTK—lymph node—thymus cancer	0.000353	0.00229	CbGeAlD
Dasatinib—MAP2K5—cardiac atrium—thymus cancer	0.000351	0.00228	CbGeAlD
Dasatinib—FMO3—lung—thymus cancer	0.000349	0.00227	CbGeAlD
Dasatinib—TNK2—lymph node—thymus cancer	0.000348	0.00226	CbGeAlD
Dasatinib—EPHB6—thyroid gland—thymus cancer	0.000346	0.00225	CbGeAlD
Dasatinib—EPHB4—lung—thymus cancer	0.000344	0.00223	CbGeAlD
Dasatinib—MAP2K5—pituitary gland—thymus cancer	0.000343	0.00223	CbGeAlD
Dasatinib—CSF1R—cardiac atrium—thymus cancer	0.000343	0.00223	CbGeAlD
Dasatinib—JAK2—lung—thymus cancer	0.000341	0.00222	CbGeAlD
Dasatinib—EPHA2—lung—thymus cancer	0.000337	0.00219	CbGeAlD
Dasatinib—FYN—lung—thymus cancer	0.000337	0.00219	CbGeAlD
Dasatinib—YES1—bone marrow—thymus cancer	0.000335	0.00218	CbGeAlD
Dasatinib—CSF1R—pituitary gland—thymus cancer	0.000335	0.00218	CbGeAlD
Dasatinib—YES1—thyroid gland—thymus cancer	0.000334	0.00217	CbGeAlD
Dasatinib—MAP3K3—lung—thymus cancer	0.000329	0.00214	CbGeAlD
Dasatinib—MAP4K5—lung—thymus cancer	0.000329	0.00214	CbGeAlD
Dasatinib—PDGFRA—thyroid gland—thymus cancer	0.000328	0.00213	CbGeAlD
Dasatinib—TESK1—lymph node—thymus cancer	0.000327	0.00213	CbGeAlD
Dasatinib—EPHB3—lymph node—thymus cancer	0.000322	0.00209	CbGeAlD
Dasatinib—STK36—lymph node—thymus cancer	0.000322	0.00209	CbGeAlD
Dasatinib—SRC—thyroid gland—thymus cancer	0.000322	0.00209	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—thymus cancer	0.000318	0.00207	CbGeAlD
Dasatinib—EPHB6—lung—thymus cancer	0.000314	0.00204	CbGeAlD
Dasatinib—LIMK2—lymph node—thymus cancer	0.000311	0.00202	CbGeAlD
Dasatinib—KIT—pituitary gland—thymus cancer	0.000304	0.00198	CbGeAlD
Dasatinib—PDGFRB—cardiac atrium—thymus cancer	0.000304	0.00198	CbGeAlD
Dasatinib—YES1—lung—thymus cancer	0.000304	0.00197	CbGeAlD
Dasatinib—CYP1B1—hematopoietic system—thymus cancer	0.000302	0.00196	CbGeAlD
Dasatinib—STK35—lymph node—thymus cancer	0.000302	0.00196	CbGeAlD
Dasatinib—CSK—lymph node—thymus cancer	0.0003	0.00195	CbGeAlD
Dasatinib—PDGFRA—lung—thymus cancer	0.000298	0.00194	CbGeAlD
Dasatinib—PDGFRB—pituitary gland—thymus cancer	0.000297	0.00193	CbGeAlD
Dasatinib—MAP2K5—thyroid gland—thymus cancer	0.000296	0.00192	CbGeAlD
Dasatinib—HCK—lymph node—thymus cancer	0.000296	0.00192	CbGeAlD
Dasatinib—ABL2—lymph node—thymus cancer	0.000294	0.00191	CbGeAlD
Dasatinib—SRC—lung—thymus cancer	0.000292	0.0019	CbGeAlD
Dasatinib—CSF1R—bone marrow—thymus cancer	0.00029	0.00188	CbGeAlD
Dasatinib—CSF1R—thyroid gland—thymus cancer	0.000289	0.00188	CbGeAlD
Dasatinib—KIT—lymphoid tissue—thymus cancer	0.000289	0.00188	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—thymus cancer	0.000282	0.00183	CbGeAlD
Dasatinib—RIPK2—lymph node—thymus cancer	0.000278	0.00181	CbGeAlD
Dasatinib—SIK1—lymph node—thymus cancer	0.000272	0.00176	CbGeAlD
Dasatinib—ABL1—cardiac atrium—thymus cancer	0.000271	0.00176	CbGeAlD
Dasatinib—EPHA4—lymph node—thymus cancer	0.000269	0.00175	CbGeAlD
Dasatinib—MAP2K5—lung—thymus cancer	0.000269	0.00175	CbGeAlD
Dasatinib—ERBB3—lymph node—thymus cancer	0.000266	0.00173	CbGeAlD
Dasatinib—ABL1—pituitary gland—thymus cancer	0.000265	0.00172	CbGeAlD
Dasatinib—MAP3K2—lymph node—thymus cancer	0.000264	0.00171	CbGeAlD
Dasatinib—KIT—bone marrow—thymus cancer	0.000263	0.00171	CbGeAlD
Dasatinib—CSF1R—lung—thymus cancer	0.000262	0.0017	CbGeAlD
Dasatinib—KIT—thyroid gland—thymus cancer	0.000262	0.0017	CbGeAlD
Dasatinib—PDGFRB—bone marrow—thymus cancer	0.000257	0.00167	CbGeAlD
Dasatinib—PDGFRB—thyroid gland—thymus cancer	0.000256	0.00166	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—thymus cancer	0.000251	0.00163	CbGeAlD
Dasatinib—MAPK14—lymph node—thymus cancer	0.000248	0.00161	CbGeAlD
Dasatinib—FGR—lymph node—thymus cancer	0.000247	0.0016	CbGeAlD
Dasatinib—LCK—lymph node—thymus cancer	0.000247	0.0016	CbGeAlD
Dasatinib—FMO3—lymph node—thymus cancer	0.000238	0.00155	CbGeAlD
Dasatinib—KIT—lung—thymus cancer	0.000238	0.00155	CbGeAlD
Dasatinib—EPHB4—lymph node—thymus cancer	0.000235	0.00153	CbGeAlD
Dasatinib—JAK2—lymph node—thymus cancer	0.000233	0.00152	CbGeAlD
Dasatinib—PDGFRB—lung—thymus cancer	0.000233	0.00151	CbGeAlD
Dasatinib—EPHA2—lymph node—thymus cancer	0.000231	0.0015	CbGeAlD
Dasatinib—FYN—lymph node—thymus cancer	0.00023	0.0015	CbGeAlD
Dasatinib—ABL1—bone marrow—thymus cancer	0.000229	0.00149	CbGeAlD
Dasatinib—ABL1—thyroid gland—thymus cancer	0.000228	0.00148	CbGeAlD
Dasatinib—MAP4K5—lymph node—thymus cancer	0.000225	0.00146	CbGeAlD
Dasatinib—MAP3K3—lymph node—thymus cancer	0.000225	0.00146	CbGeAlD
Dasatinib—CYP1B1—pituitary gland—thymus cancer	0.000224	0.00146	CbGeAlD
Dasatinib—CYP1A2—hematopoietic system—thymus cancer	0.000217	0.00141	CbGeAlD
Dasatinib—EPHB6—lymph node—thymus cancer	0.000215	0.0014	CbGeAlD
Dasatinib—CYP1A1—hematopoietic system—thymus cancer	0.000214	0.00139	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—thymus cancer	0.000213	0.00138	CbGeAlD
Dasatinib—CYP3A5—hematopoietic system—thymus cancer	0.000209	0.00136	CbGeAlD
Dasatinib—YES1—lymph node—thymus cancer	0.000208	0.00135	CbGeAlD
Dasatinib—ABL1—lung—thymus cancer	0.000207	0.00135	CbGeAlD
Dasatinib—PDGFRA—lymph node—thymus cancer	0.000204	0.00132	CbGeAlD
Dasatinib—SRC—lymph node—thymus cancer	0.0002	0.0013	CbGeAlD
Dasatinib—CYP1A1—epithelium—thymus cancer	0.000195	0.00127	CbGeAlD
Dasatinib—CYP1B1—thyroid gland—thymus cancer	0.000193	0.00126	CbGeAlD
Dasatinib—MAP2K5—lymph node—thymus cancer	0.000184	0.00119	CbGeAlD
Dasatinib—CSF1R—lymph node—thymus cancer	0.000179	0.00117	CbGeAlD
Dasatinib—CYP1B1—lung—thymus cancer	0.000176	0.00114	CbGeAlD
Dasatinib—ABCG2—pituitary gland—thymus cancer	0.000167	0.00108	CbGeAlD
Dasatinib—KIT—lymph node—thymus cancer	0.000163	0.00106	CbGeAlD
Dasatinib—CYP1A1—cardiac atrium—thymus cancer	0.000162	0.00105	CbGeAlD
Dasatinib—PDGFRB—lymph node—thymus cancer	0.000159	0.00103	CbGeAlD
Dasatinib—CYP3A4—hematopoietic system—thymus cancer	0.000157	0.00102	CbGeAlD
Dasatinib—ABCG2—bone marrow—thymus cancer	0.000144	0.000938	CbGeAlD
Dasatinib—ABCG2—thyroid gland—thymus cancer	0.000144	0.000935	CbGeAlD
Dasatinib—ABL1—lymph node—thymus cancer	0.000142	0.000921	CbGeAlD
Dasatinib—CYP1A2—thyroid gland—thymus cancer	0.000139	0.0009	CbGeAlD
Dasatinib—CYP1A1—thyroid gland—thymus cancer	0.000137	0.000888	CbGeAlD
Dasatinib—ABCG2—lung—thymus cancer	0.000131	0.000849	CbGeAlD
Dasatinib—CYP1A2—lung—thymus cancer	0.000126	0.000818	CbGeAlD
Dasatinib—CYP1A1—lung—thymus cancer	0.000124	0.000806	CbGeAlD
Dasatinib—CYP3A5—lung—thymus cancer	0.000121	0.000789	CbGeAlD
Dasatinib—CYP1B1—lymph node—thymus cancer	0.00012	0.00078	CbGeAlD
Dasatinib—ABCB1—hematopoietic system—thymus cancer	0.000111	0.000721	CbGeAlD
Dasatinib—ABCB1—epithelium—thymus cancer	0.000101	0.000659	CbGeAlD
Dasatinib—ABCG2—lymph node—thymus cancer	8.94e-05	0.000581	CbGeAlD
Dasatinib—CYP1A1—lymph node—thymus cancer	8.49e-05	0.000552	CbGeAlD
Dasatinib—ABCB1—pituitary gland—thymus cancer	8.23e-05	0.000535	CbGeAlD
Dasatinib—ABCB1—lymphoid tissue—thymus cancer	7.82e-05	0.000508	CbGeAlD
Dasatinib—ABCB1—bone marrow—thymus cancer	7.12e-05	0.000462	CbGeAlD
Dasatinib—ABCB1—thyroid gland—thymus cancer	7.1e-05	0.000461	CbGeAlD
Dasatinib—ABCB1—lung—thymus cancer	6.45e-05	0.000419	CbGeAlD
Dasatinib—ABCB1—lymph node—thymus cancer	4.41e-05	0.000286	CbGeAlD
Dasatinib—HCK—Immune System—IL2—thymus cancer	1.91e-05	0.000141	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—CD4—thymus cancer	1.91e-05	0.000141	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—CD4—thymus cancer	1.9e-05	0.00014	CbGpPWpGaD
Dasatinib—LCK—B Cell Activation—AKT1—thymus cancer	1.89e-05	0.000139	CbGpPWpGaD
Dasatinib—BLK—Immune System—CD4—thymus cancer	1.89e-05	0.000139	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—IL2—thymus cancer	1.88e-05	0.000138	CbGpPWpGaD
Dasatinib—FGR—Immune System—CD4—thymus cancer	1.88e-05	0.000138	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD8A—thymus cancer	1.87e-05	0.000137	CbGpPWpGaD
Dasatinib—BTK—Adaptive Immune System—AKT1—thymus cancer	1.87e-05	0.000137	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—CD4—thymus cancer	1.86e-05	0.000137	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—IL2—thymus cancer	1.86e-05	0.000137	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD8A—thymus cancer	1.84e-05	0.000135	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KIT—thymus cancer	1.84e-05	0.000135	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—CD4—thymus cancer	1.84e-05	0.000135	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—CD4—thymus cancer	1.84e-05	0.000135	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—CD4—thymus cancer	1.82e-05	0.000134	CbGpPWpGaD
Dasatinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.81e-05	0.000133	CbGpPWpGaD
Dasatinib—SRC—Signaling by FGFR in disease—AKT1—thymus cancer	1.81e-05	0.000133	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL2—thymus cancer	1.8e-05	0.000133	CbGpPWpGaD
Dasatinib—SRC—Signaling by EGFR—AKT1—thymus cancer	1.79e-05	0.000132	CbGpPWpGaD
Dasatinib—FGR—Hemostasis—AKT1—thymus cancer	1.79e-05	0.000131	CbGpPWpGaD
Dasatinib—HCK—Innate Immune System—AKT1—thymus cancer	1.78e-05	0.000131	CbGpPWpGaD
Dasatinib—SRC—Signaling by EGFR in Cancer—AKT1—thymus cancer	1.78e-05	0.000131	CbGpPWpGaD
Dasatinib—SRC—Signaling by PDGF—AKT1—thymus cancer	1.77e-05	0.00013	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KIT—thymus cancer	1.77e-05	0.00013	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by NGF—AKT1—thymus cancer	1.74e-05	0.000128	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL2—thymus cancer	1.73e-05	0.000128	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL2—thymus cancer	1.73e-05	0.000127	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—CD4—thymus cancer	1.73e-05	0.000127	CbGpPWpGaD
Dasatinib—LCK—Platelet activation, signaling and aggregation—AKT1—thymus cancer	1.71e-05	0.000126	CbGpPWpGaD
Dasatinib—SRC—Membrane Trafficking—AKT1—thymus cancer	1.71e-05	0.000126	CbGpPWpGaD
Dasatinib—SRC—Focal Adhesion—AKT1—thymus cancer	1.71e-05	0.000126	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—TP53—thymus cancer	1.71e-05	0.000126	CbGpPWpGaD
Dasatinib—MAPK14—Metabolism of RNA—AKT1—thymus cancer	1.71e-05	0.000125	CbGpPWpGaD
Dasatinib—SRC—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.7e-05	0.000125	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAML2—thymus cancer	1.7e-05	0.000125	CbGpPWpGaD
Dasatinib—RIPK2—Innate Immune System—AKT1—thymus cancer	1.68e-05	0.000123	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KIT—thymus cancer	1.68e-05	0.000123	CbGpPWpGaD
Dasatinib—FYN—Signaling by NGF—AKT1—thymus cancer	1.67e-05	0.000123	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KIT—thymus cancer	1.66e-05	0.000122	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—IL2—thymus cancer	1.63e-05	0.00012	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD8A—thymus cancer	1.61e-05	0.000119	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL2—thymus cancer	1.61e-05	0.000119	CbGpPWpGaD
Dasatinib—RIPK2—Adaptive Immune System—AKT1—thymus cancer	1.61e-05	0.000119	CbGpPWpGaD
Dasatinib—MAPK14—Signaling by NGF—AKT1—thymus cancer	1.61e-05	0.000118	CbGpPWpGaD
Dasatinib—FGR—Innate Immune System—AKT1—thymus cancer	1.61e-05	0.000118	CbGpPWpGaD
Dasatinib—SRC—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.6e-05	0.000118	CbGpPWpGaD
Dasatinib—ERBB3—Disease—CD4—thymus cancer	1.6e-05	0.000117	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—CD4—thymus cancer	1.59e-05	0.000117	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL2—thymus cancer	1.59e-05	0.000117	CbGpPWpGaD
Dasatinib—JAK2—Signaling by NGF—AKT1—thymus cancer	1.59e-05	0.000117	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL2—thymus cancer	1.56e-05	0.000115	CbGpPWpGaD
Dasatinib—BLK—Adaptive Immune System—AKT1—thymus cancer	1.55e-05	0.000114	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KIT—thymus cancer	1.55e-05	0.000114	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—CD4—thymus cancer	1.53e-05	0.000112	CbGpPWpGaD
Dasatinib—YES1—Immune System—CD4—thymus cancer	1.52e-05	0.000111	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KIT—thymus cancer	1.52e-05	0.000111	CbGpPWpGaD
Dasatinib—SRC—Platelet activation, signaling and aggregation—AKT1—thymus cancer	1.52e-05	0.000111	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KIT—thymus cancer	1.51e-05	0.000111	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAML2—thymus cancer	1.5e-05	0.00011	CbGpPWpGaD
Dasatinib—ERBB3—Innate Immune System—AKT1—thymus cancer	1.48e-05	0.000109	CbGpPWpGaD
Dasatinib—LYN—Immune System—KIT—thymus cancer	1.48e-05	0.000109	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KIT—thymus cancer	1.47e-05	0.000108	CbGpPWpGaD
Dasatinib—YES1—Developmental Biology—AKT1—thymus cancer	1.47e-05	0.000108	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TP53—thymus cancer	1.47e-05	0.000108	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KIT—thymus cancer	1.46e-05	0.000107	CbGpPWpGaD
Dasatinib—FYN—Immune System—KIT—thymus cancer	1.46e-05	0.000107	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—AKT1—thymus cancer	1.44e-05	0.000106	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—IL2—thymus cancer	1.44e-05	0.000106	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD8A—thymus cancer	1.43e-05	0.000105	CbGpPWpGaD
Dasatinib—ERBB3—Adaptive Immune System—AKT1—thymus cancer	1.42e-05	0.000104	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—CD4—thymus cancer	1.41e-05	0.000104	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KIT—thymus cancer	1.4e-05	0.000103	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL2—thymus cancer	1.4e-05	0.000103	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KIT—thymus cancer	1.39e-05	0.000102	CbGpPWpGaD
Dasatinib—LCK—Signaling by NGF—AKT1—thymus cancer	1.39e-05	0.000102	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KIT—thymus cancer	1.38e-05	0.000102	CbGpPWpGaD
Dasatinib—KIT—Immune System—CD4—thymus cancer	1.35e-05	9.96e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—CD4—thymus cancer	1.35e-05	9.95e-05	CbGpPWpGaD
Dasatinib—CSK—Immune System—AKT1—thymus cancer	1.35e-05	9.94e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KIT—thymus cancer	1.34e-05	9.88e-05	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—AKT1—thymus cancer	1.31e-05	9.63e-05	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—AKT1—thymus cancer	1.3e-05	9.55e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CD4—thymus cancer	1.28e-05	9.42e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KIT—thymus cancer	1.28e-05	9.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KIT—thymus cancer	1.28e-05	9.39e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—thymus cancer	1.27e-05	9.37e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—thymus cancer	1.27e-05	9.32e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—thymus cancer	1.25e-05	9.22e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—CD4—thymus cancer	1.25e-05	9.19e-05	CbGpPWpGaD
Dasatinib—CSK—Disease—AKT1—thymus cancer	1.25e-05	9.18e-05	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—AKT1—thymus cancer	1.25e-05	9.17e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL2—thymus cancer	1.25e-05	9.16e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—AKT1—thymus cancer	1.24e-05	9.12e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—AKT1—thymus cancer	1.23e-05	9.06e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KIT—thymus cancer	1.21e-05	8.91e-05	CbGpPWpGaD
Dasatinib—STAT5B—Disease—AKT1—thymus cancer	1.21e-05	8.89e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—thymus cancer	1.21e-05	8.88e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.19e-05	8.77e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—thymus cancer	1.19e-05	8.77e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—CD4—thymus cancer	1.18e-05	8.7e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL2—thymus cancer	1.18e-05	8.67e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—IL2—thymus cancer	1.17e-05	8.63e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL2—thymus cancer	1.17e-05	8.57e-05	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—AKT1—thymus cancer	1.16e-05	8.55e-05	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—AKT1—thymus cancer	1.16e-05	8.53e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CD4—thymus cancer	1.16e-05	8.49e-05	CbGpPWpGaD
Dasatinib—BTK—Immune System—AKT1—thymus cancer	1.13e-05	8.32e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CD4—thymus cancer	1.13e-05	8.31e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD4—thymus cancer	1.13e-05	8.27e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KIT—thymus cancer	1.12e-05	8.23e-05	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—AKT1—thymus cancer	1.11e-05	8.19e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD4—thymus cancer	1.11e-05	8.18e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—AKT1—thymus cancer	1.1e-05	8.07e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—AKT1—thymus cancer	1.1e-05	8.06e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—AKT1—thymus cancer	1.09e-05	8.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KIT—thymus cancer	1.08e-05	7.97e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—AKT1—thymus cancer	1.08e-05	7.94e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—AKT1—thymus cancer	1.08e-05	7.91e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KIT—thymus cancer	1.07e-05	7.89e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD4—thymus cancer	1.07e-05	7.88e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—AKT1—thymus cancer	1.07e-05	7.87e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CD4—thymus cancer	1.07e-05	7.84e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL2—thymus cancer	1.07e-05	7.84e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL2—thymus cancer	1.07e-05	7.83e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL2—thymus cancer	1.06e-05	7.81e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—AKT1—thymus cancer	1.06e-05	7.79e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD4—thymus cancer	1.06e-05	7.78e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—AKT1—thymus cancer	1.05e-05	7.75e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—thymus cancer	1.04e-05	7.68e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL2—thymus cancer	1.04e-05	7.65e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—AKT1—thymus cancer	1.04e-05	7.64e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—AKT1—thymus cancer	1.04e-05	7.63e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL2—thymus cancer	1.04e-05	7.61e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—thymus cancer	1.04e-05	7.61e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CD4—thymus cancer	1.03e-05	7.56e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL2—thymus cancer	1.03e-05	7.56e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—AKT1—thymus cancer	1.03e-05	7.55e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL2—thymus cancer	1.02e-05	7.53e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—AKT1—thymus cancer	1.02e-05	7.5e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.01e-05	7.4e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—AKT1—thymus cancer	1.01e-05	7.4e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—thymus cancer	1e-05	7.37e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KIT—thymus cancer	9.91e-06	7.28e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—AKT1—thymus cancer	9.9e-06	7.27e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL2—thymus cancer	9.87e-06	7.25e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—AKT1—thymus cancer	9.78e-06	7.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CD4—thymus cancer	9.77e-06	7.18e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KIT—thymus cancer	9.77e-06	7.18e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL2—thymus cancer	9.74e-06	7.16e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—AKT1—thymus cancer	9.69e-06	7.12e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—AKT1—thymus cancer	9.64e-06	7.09e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—AKT1—thymus cancer	9.59e-06	7.05e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KIT—thymus cancer	9.56e-06	7.03e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—AKT1—thymus cancer	9.54e-06	7.01e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—AKT1—thymus cancer	9.5e-06	6.98e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KIT—thymus cancer	9.41e-06	6.92e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—AKT1—thymus cancer	9.41e-06	6.91e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—AKT1—thymus cancer	9.38e-06	6.89e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—AKT1—thymus cancer	9.3e-06	6.84e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD4—thymus cancer	9.27e-06	6.81e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—thymus cancer	9.25e-06	6.8e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—AKT1—thymus cancer	9.19e-06	6.75e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—AKT1—thymus cancer	9.16e-06	6.73e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—AKT1—thymus cancer	9.07e-06	6.66e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KIT—thymus cancer	9.06e-06	6.66e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL2—thymus cancer	9.02e-06	6.63e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KIT—thymus cancer	8.95e-06	6.58e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—AKT1—thymus cancer	8.82e-06	6.48e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—AKT1—thymus cancer	8.75e-06	6.43e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—AKT1—thymus cancer	8.62e-06	6.34e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CD4—thymus cancer	8.56e-06	6.29e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL2—thymus cancer	8.53e-06	6.27e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—AKT1—thymus cancer	8.48e-06	6.24e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—AKT1—thymus cancer	8.47e-06	6.23e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD4—thymus cancer	8.21e-06	6.03e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL2—thymus cancer	8.06e-06	5.92e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—AKT1—thymus cancer	7.96e-06	5.85e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—AKT1—thymus cancer	7.96e-06	5.85e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—AKT1—thymus cancer	7.94e-06	5.84e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KIT—thymus cancer	7.84e-06	5.76e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—AKT1—thymus cancer	7.81e-06	5.74e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL2—thymus cancer	7.63e-06	5.61e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—AKT1—thymus cancer	7.63e-06	5.6e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CD4—thymus cancer	7.58e-06	5.57e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—AKT1—thymus cancer	7.57e-06	5.56e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL2—thymus cancer	7.55e-06	5.55e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—thymus cancer	7.49e-06	5.5e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—thymus cancer	7.03e-06	5.17e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KIT—thymus cancer	6.94e-06	5.1e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—thymus cancer	6.87e-06	5.05e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—thymus cancer	6.85e-06	5.03e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—thymus cancer	6.76e-06	4.97e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—thymus cancer	6.75e-06	4.96e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—thymus cancer	6.73e-06	4.95e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—thymus cancer	6.62e-06	4.87e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—thymus cancer	6.6e-06	4.85e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—thymus cancer	6.4e-06	4.7e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—thymus cancer	6.38e-06	4.69e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—thymus cancer	6.37e-06	4.68e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—thymus cancer	6.32e-06	4.65e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—thymus cancer	6.3e-06	4.63e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—thymus cancer	6.24e-06	4.59e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—thymus cancer	5.91e-06	4.34e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—thymus cancer	5.79e-06	4.26e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—thymus cancer	5.78e-06	4.25e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—thymus cancer	5.78e-06	4.25e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—thymus cancer	5.76e-06	4.24e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—thymus cancer	5.64e-06	4.15e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—thymus cancer	5.62e-06	4.13e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—thymus cancer	5.57e-06	4.1e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—thymus cancer	5.56e-06	4.08e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—thymus cancer	5.52e-06	4.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—thymus cancer	5.35e-06	3.93e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—thymus cancer	5.32e-06	3.91e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—thymus cancer	5.32e-06	3.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—thymus cancer	5.28e-06	3.88e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—thymus cancer	5.17e-06	3.8e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—thymus cancer	5.13e-06	3.77e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—thymus cancer	4.9e-06	3.6e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—thymus cancer	4.89e-06	3.6e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—thymus cancer	4.88e-06	3.59e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—thymus cancer	4.88e-06	3.58e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—thymus cancer	4.63e-06	3.4e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—thymus cancer	4.41e-06	3.24e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—thymus cancer	4.37e-06	3.21e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—thymus cancer	4.32e-06	3.18e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—thymus cancer	4.27e-06	3.14e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—thymus cancer	4.25e-06	3.13e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—thymus cancer	4.14e-06	3.04e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—thymus cancer	4.1e-06	3.01e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—thymus cancer	4.09e-06	3.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—thymus cancer	4.04e-06	2.97e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—thymus cancer	3.81e-06	2.8e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—thymus cancer	3.78e-06	2.78e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—thymus cancer	3.73e-06	2.74e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—thymus cancer	3.65e-06	2.68e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—thymus cancer	3.59e-06	2.64e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—thymus cancer	3.54e-06	2.6e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—thymus cancer	3.46e-06	2.55e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—thymus cancer	3.46e-06	2.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—thymus cancer	3.41e-06	2.51e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—thymus cancer	3.14e-06	2.3e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—thymus cancer	2.99e-06	2.2e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—thymus cancer	2.65e-06	1.95e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—thymus cancer	2.48e-06	1.82e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—thymus cancer	2.35e-06	1.72e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—thymus cancer	1.87e-06	1.38e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—thymus cancer	1.5e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—thymus cancer	1.15e-06	8.48e-06	CbGpPWpGaD
